Depression

PCN Issues Warning About Hepatotoxity With Use of Serzone

Published in Hepatitis Weekly, February 11th, 2002

Pharmaceutical Care Network (PCN), a pharmacy benefit manager (PBM), is alerting physicians of the new black box warning for Serzone (nefazodone), a medication commonly used for the treatment of depression.

Cases of life-threatening hepatic failure resulting in transplantations or deaths have been reported in patients treated with Serzone at a rate of 1 case per 250,000 to 300,000 patient-years of Serzone treatment. The U.S. Food and Drug Administration (FDA) has advised that treatment with Serzone should not be initiated in individuals with active liver disease or with elevated baseline serum transaminases. Patients who develop evidence of hepatocellular injury, such...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2002-02-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry